Tat analog + AT1002 analog (AT-1002)
Sequence: GRKKRRQRRRCG | FCIGRLCG
| Experiment Id | EXP001844 |
|---|---|
| Paper | Development of an Efficient Transdermal Delivery System of Small Interfering RNA Using Functional Pe |
| Peptide | Tat analog + AT1002 analog (AT-1002) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | Tat/siRNA at N/P 10, then AT1002 added (AT1002:siRNA weight ratio 80:1) |
| Formulation Format | Tat/siRNA nanocomplex + AT1002 co-formulation |
| Formulation Components | Tat/siRelA complex incubated then mixed with AT1002; evaluated for RNaseA protection |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | |
| Animal Model | |
| Administration Route | |
| Output Type | siRNA stability against RNaseA |
| Output Value | ~60% siRNA remaining after 10 h RNaseA (strongest protection among conditions) |
| Output Units | |
| Output Notes | Demonstrates synergistic stabilization of siRNA by Tat + AT1002. |
| Toxicity Notes | |
| Curation Notes |